Close this search box.

Seventeen Minutes of Science: Engineering a Cure for Fragile X

Tune in weekly to our virtual series “Seventeen Minutes of Science” every Tuesday at 11am PST / 2pm ET where we go live on Facebook with a new guest each week to talk about how science and biotechnology is woven into their lives for (you guessed it) 17 minutes!

For Episode 23 of 17 Minutes of Science we are joined by Dave Bjork. Dave is the director of Community Relations at FRAXA Research Foundation, the Founder of FRAXA Biotech Games, and a Patient Advocate. He has more than 20 years of progressive experience in nonprofit marketing, patient advocacy and fundraising leadership roles including Vice President of Development, National Foundation for Cancer Research, Bethesda, MD. In this role, he launched several fundraising programs and became known as the “Cancer Research Evangelist” because of his dedication and commitment to basic scientific research. Bjork has made it his life mission to connect individuals, businesses, academic institutions and other key influencers to forge strong partnerships to focus on research. In his role at FRAXA, he is actively building strong relationships with Fragile X families and the scientific community. He also advocates for the important role patient groups play in working with the biopharma industry. Bjork earned a BS in Economics and Finance from the Wharton School at the University of Pennsylvania.

Dave joins us to discuss Fragile X, what it is, progress being made towards a cure, and his work to raise awareness for the disease.

Tune in to learn more about Fragile X from Dave Bjork.

About The Author

InVivo Biosystems

InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.

Share this articles

Picture of InVivo Biosystems

About the Author:

Connect with us